The six finalists in the 2012 Venture Showcase competition include:
Flashback Technologies Inc. - Longmont, CO - is developing and commercializing product applications of its proprietary software algorithm platform called CipherSensorTM Technology. The first product application is in the medical trauma setting enabling the immediate, noninvasive detection of the risk for cardiovascular collapse and monitoring of the effectiveness of fluid resuscitation therapy. http://www.flashbacktechnologies.com
KromaTiD - Fort Collins, CO - makes products for analyzing defects and damage to human chromosomes. The company is launching the first commercial platform for the discovery and detection of a recalcitrant class of DNA mutations known as Chromosomal Inversions. http://www.kromatid.com
Siva Therapeutics Inc. - Boulder, CO - is developing a method for cancer therapy which promises to be safer, with fewer side effects, and at least as effective as current therapies. The company’s approach is precision photothermal treatment of solid tumors using targeted gold nanorods - SivaRods™. http://www.sivatherapeutics.com
Sophono Inc. - Boulder, CO - has developed the world’s first non-percutaneous, implantable, bone-anchored hearing device. The company’s Alpha 1 System eliminates the problematic abutment of other devices by using magnets to securely affix the external sound processor to a titanium implant. http://www.sophono.com
SuviCa Inc. - Boulder, CO - is a biotechnology company focused on the discovery and development of small molecule drugs for oncology. The company’s family of compounds target a process crucial for cancer growth but under-utilized as a drug target. http://www.suvica.com
VetDC Inc. - Fort Collins, CO - is an emergent veterinary biotechnology company that licenses innovative human biomedical technologies to address serious unmet medical needs in companion animals. The company’s lead candidate is a novel anti-cancer drug. http://www.vet-dc.com
The Venture Showcase finalists pitch their technologies and business plans in front of a live audience at BioWest to a panel of bioscience experts and venture capitalists. The winner, announced at the end of the conference day, will receive a $7,500 cash prize.